The need for worldwide policy and action plans for rare diseases
暂无分享,去创建一个
Domenica Taruscio | Désirée Gavhed | Manuel Posada | D. Taruscio | D. Gavhed | T. Coté | S. Groft | M. Posada | Catarina Edfjäll | J. Henter | E. Tambuyzer | Stephen C Groft | J. Forman | Jan-Inge Henter | Erik Tambuyzer | Timothy R Coté | John Forman | Virginia A Llera | Luis A Barrera | Catarina Edfjäll | Marlene E Haffner | Yukiko Nishimura | M. Haffner | Virginia A. Llera | Yukiko Nishimura
[1] Ségolène Aymé,et al. Empowerment of patients: lessons from the rare diseases community , 2008, The Lancet.
[2] M. Moses,et al. Two decades of orphan product development , 2002, Nature Reviews Drug Discovery.
[3] J. Henter,et al. Cytotoxic therapy for severe swine flu A/H1N1 , 2010, The Lancet.
[4] Martin Stanulla,et al. Treatment of childhood acute lymphoblastic leukemia. , 2009, Seminars in hematology.
[5] B. Fadeel,et al. A journey of hope: lessons learned from studies on rare diseases and orphan drugs , 2006, Journal of internal medicine.
[6] A. Fischer. Human primary immunodeficiency diseases: a perspective , 2004, Nature Immunology.
[7] Sabine Urban. Europe’s Challenges , 1996 .